Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9668119rdf:typepubmed:Citationlld:pubmed
pubmed-article:9668119lifeskim:mentionsumls-concept:C1335858lld:lifeskim
pubmed-article:9668119lifeskim:mentionsumls-concept:C0524637lld:lifeskim
pubmed-article:9668119lifeskim:mentionsumls-concept:C0148199lld:lifeskim
pubmed-article:9668119lifeskim:mentionsumls-concept:C1442756lld:lifeskim
pubmed-article:9668119lifeskim:mentionsumls-concept:C1519249lld:lifeskim
pubmed-article:9668119lifeskim:mentionsumls-concept:C0597360lld:lifeskim
pubmed-article:9668119lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:9668119lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:9668119pubmed:issue30lld:pubmed
pubmed-article:9668119pubmed:dateCreated1998-8-20lld:pubmed
pubmed-article:9668119pubmed:abstractTextKinase domain receptor (KDR) is a high affinity, endothelial cell-specific, autophosphorylating tyrosine kinase receptor for vascular endothelial growth factor. This transcriptionally regulated receptor is a critical mediator of endothelial cell (EC) growth and vascular development. In this study, we identify a DNA element modulating KDR promoter activity and evaluate the nuclear binding proteins accounting for a portion of the cell-type specificity of the region. KDR promoter luciferase activity was retained within -85/+296 and was 10-30-fold higher in EC than non-EC. Electrophoretic mobility shift assays demonstrated specific nuclear protein binding to -85/-64, and single point mutations suggested important binding nucleotides between -79/-68 with five critical bases between -74/-70 (5'-CTCCT-3'). DNA-protein complexes were displaced by Sp1 consensus sequence oligodeoxynucleotides and supershifted by Sp1- and Sp3-specific antibodies. Sp1 and Sp3 protein in EC nuclear extracts bound the -79/-68 region even when all surrounding classic Sp1 recognition sites were removed. Sp1 protein in nuclear extracts was 4-24-fold higher in EC than non-EC, whereas Sp3 was 3-7-fold higher. Sp1/Sp3 ratios in EC were 2-10-fold higher. Overexpression of Sp1 protein increased KDR promoter activity 3-fold in both EC and non-EC, whereas simultaneous co-expression of Sp3 attenuated this response. An Sp1 consensus sequence cis element "decoy" reduced EC KDR promoter activity and mRNA expression by 85 and 69%, respectively. An antisense phosphorothioate oligodeoxynucleotide to Sp1 inhibited Sp1 and KDR protein expression by 66 and 68%, respectively, without changing Sp3 protein expression. These data illustrate that Sp1 and Sp3 modulate KDR promoter activity through a novel recognition binding sequence. However, since Sp1-mediated promoter activation is attenuated by Sp3, endothelial selective KDR promoter activity may be partially regulated by variations in the Sp1/Sp3 ratio.lld:pubmed
pubmed-article:9668119pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9668119pubmed:languageenglld:pubmed
pubmed-article:9668119pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9668119pubmed:citationSubsetIMlld:pubmed
pubmed-article:9668119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9668119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9668119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9668119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9668119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9668119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9668119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9668119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9668119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9668119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9668119pubmed:statusMEDLINElld:pubmed
pubmed-article:9668119pubmed:monthJullld:pubmed
pubmed-article:9668119pubmed:issn0021-9258lld:pubmed
pubmed-article:9668119pubmed:authorpubmed-author:HataYYlld:pubmed
pubmed-article:9668119pubmed:authorpubmed-author:ZhangKKlld:pubmed
pubmed-article:9668119pubmed:authorpubmed-author:RobinsonG SGSlld:pubmed
pubmed-article:9668119pubmed:authorpubmed-author:AielloL PLPlld:pubmed
pubmed-article:9668119pubmed:authorpubmed-author:DumNNlld:pubmed
pubmed-article:9668119pubmed:issnTypePrintlld:pubmed
pubmed-article:9668119pubmed:day24lld:pubmed
pubmed-article:9668119pubmed:volume273lld:pubmed
pubmed-article:9668119pubmed:ownerNLMlld:pubmed
pubmed-article:9668119pubmed:authorsCompleteYlld:pubmed
pubmed-article:9668119pubmed:pagination19294-303lld:pubmed
pubmed-article:9668119pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:meshHeadingpubmed-meshheading:9668119-...lld:pubmed
pubmed-article:9668119pubmed:year1998lld:pubmed
pubmed-article:9668119pubmed:articleTitleTranscription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence.lld:pubmed
pubmed-article:9668119pubmed:affiliationResearch Division, Joslin Diabetes Center, Boston, Massachusetts 02215, USA.lld:pubmed
pubmed-article:9668119pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9668119pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9668119pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9668119lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9668119lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9668119lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9668119lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9668119lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9668119lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9668119lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9668119lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9668119lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9668119lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9668119lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9668119lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9668119lld:pubmed